-
Mashup Score: 3Urology Cancer Summit - 27 day(s) ago
The First International Urology Cancer Summit is a free and independent educational opportunity open to everyone involved in caring for patients with urologic cancers.
Source: urologycancersummit.orgCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 3Urology Cancer Summit - 27 day(s) ago
The First International Urology Cancer Summit is a free and independent educational opportunity open to everyone involved in caring for patients with urologic cancers.
Source: urologycancersummit.orgCategories: General Medicine News, Oncologists2Tweet-
RT @urologysummit: Neeraj Agarwal is one of the #IUCS23 speakers. Discover more here ➡️https://t.co/RXbCFkCa4h #urology #cancer @neerajaiims
-
-
Mashup Score: 0ASCO 2025: FGFR3 Alteration Status and Outcomes with Immune Checkpoint Inhibitors in Patients with Metastatic Urothelial Carcinoma - 1 month(s) ago
ASCO 2025, bladder cancer, Metastatic Urothelial Carcinoma, FGFR3 alteration, Immune Checkpoint Inhibitors in Patients with Metastatic Urothelial Carcinoma, predictive markers for bladder cancer.
Source: www.urotoday.comCategories: General Medicine NewsTweet-
https://t.co/ZGqp827N84 via @urotoday
-
-
Mashup Score: 8100 Influential Women in Oncology: Key Opinion Leaders to Follow on Social Media in 2024: Part 7 - OncoDaily - 9 month(s) ago
100 Influential Women in Oncology: Key Opinion Leaders to Follow on Social Media in 2024: Part 7 / 100 Influential Women in Oncology, Alessandra Curioni,
Source: oncodaily.comCategories: General Medicine News, Oncologists1Tweet-
RT @oncodaily: 100 Influential Women in Oncology: Key Opinion Leaders to Follow on Social Media in 2024: Part 7 https://t.co/0WBL8nfRL8 T…
-
-
Mashup Score: 46Pfizer’s TALZENNA® in Combination with XTANDI® Prolongs Overall Survival in Phase 3 TALAPRO-2 Trial - 9 month(s) ago
Pfizer Inc. (NYSE: PFE) today announced positive topline results from the final prespecified overall survival (OS) analysis of the TALAPRO-2 study of
Source: www.businesswire.comCategories: General Medicine News, Oncologists1Tweet-
Huge congrats to @neerajaiims & team on this huge news of OS improvement with talazoparib-enza mCRPC in TALAPRO-2 trial! @montypal @PGrivasMDPhD @AzadOncology @NeliMUlrich @DrChoueiri @Huntsman_GU https://t.co/8AOGn1RZJ3
-
-
Mashup Score: 46Pfizer’s TALZENNA® in Combination with XTANDI® Prolongs Overall Survival in Phase 3 TALAPRO-2 Trial - 9 month(s) ago
Pfizer Inc. (NYSE: PFE) today announced positive topline results from the final prespecified overall survival (OS) analysis of the TALAPRO-2 study of
Source: www.businesswire.comCategories: General Medicine News, Oncologists1Tweet-
Huge congrats to @neerajaiims & team on this huge news of OS improvement with talazoparib-enza mCRPC in TALAPRO-2 trial! @montypal @PGrivasMDPhD @AzadOncology @NeliMUlrich @DrChoueiri @Huntsman_GU https://t.co/8AOGn1RZJ3
-
-
Mashup Score: 8Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce - PubMed - 11 month(s) ago
As the field of cancer immunotherapy continues to advance at a fast pace, treatment approaches and drug development are evolving rapidly to maximize patient benefit. New agents are commonly evaluated for activity in patients who had previously received a programmed death receptor 1 (PD-1)/programmed …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Oncologists1Tweet-
Must read on primary & acquired resistance to IO developed during the inaugural panel meeting. https://t.co/UtnR2WM56q
-
-
Mashup Score: 8Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce - PubMed - 11 month(s) ago
As the field of cancer immunotherapy continues to advance at a fast pace, treatment approaches and drug development are evolving rapidly to maximize patient benefit. New agents are commonly evaluated for activity in patients who had previously received a programmed death receptor 1 (PD-1)/programmed …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Oncologists1Tweet-
Must read on primary & acquired resistance to IO developed during the inaugural panel meeting. https://t.co/UtnR2WM56q
-
-
Mashup Score: 33Program Guide – ASCO Meeting Program Guide - 1 year(s) ago
Shilpa Gupta Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH Shilpa Gupta, Thomas Powles, Mairead Kearney, Laura Panattoni, Natalie Land, Thomas Flottemesch, Patrick Sullivan, Melissa Kirker, Murtuza Bharmal, Silke Guenther, Nuno Costa, Enrique Grande Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, Barts Cancer Institute, Experimental Cancer Medicine Centre, Queen Mary University of London, St Bartholomew’s Hospital, London, United Kingdom, The Healthcare Business of Merck KGaA,
Source: meetings.asco.orgCategories: General Medicine News, Oncologists2Tweet-
Glad to present our work on physician reported 1L tx patterns 5 European countries. @ASCO #ASCO24 @drenriquegrande @tompowles1 👉 >75% pts offered systemic 1L tx 👉advanced age (> med 74 yr) was a major criteria for not offering Tx @CleClinicMD https://t.co/DLopQif809 https://t.co/ubG3aMxAnj
-
-
Mashup Score: 33Program Guide – ASCO Meeting Program Guide - 1 year(s) ago
Shilpa Gupta Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH Shilpa Gupta, Thomas Powles, Mairead Kearney, Laura Panattoni, Natalie Land, Thomas Flottemesch, Patrick Sullivan, Melissa Kirker, Murtuza Bharmal, Silke Guenther, Nuno Costa, Enrique Grande Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, Barts Cancer Institute, Experimental Cancer Medicine Centre, Queen Mary University of London, St Bartholomew’s Hospital, London, United Kingdom, The Healthcare Business of Merck KGaA,
Source: meetings.asco.orgCategories: General Medicine News, Oncologists2Tweet-
Glad to present our work on physician reported 1L tx patterns 5 European countries. @ASCO #ASCO24 @drenriquegrande @tompowles1 👉 >75% pts offered systemic 1L tx 👉advanced age (> med 74 yr) was a major criteria for not offering Tx @CleClinicMD https://t.co/DLopQif809 https://t.co/ubG3aMxAnj
-
RT @urologysummit: Neeraj Agarwal is one of the #IUCS23 speakers. Discover more here ➡️https://t.co/RXbCFkCa4h #urology #cancer @neerajaiims